In the last decades several cases of association between sarcoidosis and various autoimmune diseases have been described, leading us to stress the concept of a possible common genetic "soil" of predisposition. The majority of these cases were association between sarcoidosis and generalized scleroderma, but only one case of localized scleroderma and sarcoidosis. In this report, we describe a case of a female patient in which a diagnosis of pulmonary sarcoidosis and morphea was made.
In April, 20 lOa 64-year-old female was referred to our Department of Dermatology with a 7-month history of multiple circumscribed plaques of skin hardening with variable discoloration mainly located on the trunk. A skin biopsy of these lesions showed moderate sclerosis of dennis, rarefaction of elastic fibers and a moderate degree of inflammatory infiltrate of papillary dermis. A diagnosis of cutaneous morphea was made.
The anamnesis of the patient revealed a past medical history of pulmonary sarcoidosis treated with systemic steroids without other relapses until now. In order to evaluate the pulmonary condition a chest X-ray was carried out which showed increased interstitial markings and paraiIare enlargement; BAL fluid revealed an increased cell count, with 26% of lymphocytes. The serum ratio of CD4/CD8 helper/suppressor was 1.0, therefore we performed a high resolution computer tomography (HRTC) that confirmed the interstitial fibrosis and the presence of lymphadenopathy.
Blood chemistry investigations showed a moderate increment of ESR and CRP, while a full blood count, ACE level, antinuclear antibodies and rheumatoid factor were all in the normal range. A diagnosis of relapses of pulmonary sarcoidosis of second level was made.
The patient underwent systemic steroid therapy, with regression of lung involvement and notable improvement of the erithema surrounding cutaneous morpheaform lesions.
Sarcoidosis is a rare granulomatous disease that can involve many organs. Cutaneous lesions occur in 20-35% of patients affected by sarcoidosis, and are divided into specific and non-specific ones. More common specific lesions are: maculopapules, nodules, plaques, infiltrative scars and lupus pernio, which are histologically characterized by non-caseating granulomas. Morpheafonn sarcoidosis is an uncommon clinical pattern and is clinically indistinguishable from morphea (1-2). We considered this form in the differential diagnosis for the morphemic lesions of our patient, and we fina lly excluded it for the abse nce of non-caseating granulomas in the multiple skin biopsies performed.
Nowadays, sarcoidosis is not considered among autoimmune disease because it lacks some of the Milgram & Witebsky criteria for these pathologies. Nevertheless, dysfunctions of the immune system are consistent in its pathogenesis and it has been described in association with some autoimmune disorders such as polyrniositis, Sjogren's syndrome, sys temic lupus erithematosus, and scleroderma (3) (4) .
Scleroderma is a conn ecti ve tissue disorder that ca n present in 2 distinc t clinical categories: localized and systemic. Localized form occurs in the skin and subc utaneous tissue, and can clinica lly show different variants, the most common one bein g plaque type morph ea . Both of these two diseases mainl y affect wo men, w ith an incidence peak between the second and the third decades (5 ) .
The existence of a relationship between sarco idosis and autoimmune disorders was first hypothesized in 1946 by Teilum, who described so me similarities in pati ent s aff ected by these two disea ses, postulating a common immunopathogenic mechanism. Sarcoidosis and morphea can share a common alteration ofthe immune system, principally represented by hyperactivity of the humoral immune system , defect in cell-mediated immune response with activation of T-helper lymphocytes and the development of auto-antibodies. Furthermore, in both these two diseases, T-cell helper CD4+ are present in acti ve lesions; in fact , the interaction between an antigen and the antigen presenting cell see ms to acti vate the T-cell CD4+ mediated respon se with the de velopment of the inflammatory ca scad e, medi ated by various cytokines and chemokines relea sed , that lead to formati on of non-caseating granuloma and fibro sis in sarcoidosic patients and to deposition of conn ecti ve tissue matri x by fibroblasts in morpheaform lesion s (5) (6) (7) .
In the last decades several cases of association between sarcoidosis and autoimmune diseases have been described, leading us to stress this concept sustammg it with recent acknowledgements in their pathogenesis and in genetic science. These alterations could be triggered by both genetic and environmental factors (such as viral ones), with the concept of a possible common genetic outlay of predisposition (3) . In our case we hypothesized that an exogenous agent might be responsible for the development of new activation of pulmonary sarcoidosis and worsening of morpheaform lesions, by activation of T-cell CD4+ lymphocytes in a genetically predisposed patient.
In literature, 23 cases are described of association between these two diseases in some patients, but only one other case oflocalized scleroderma and sarcoidosis (6) . Nevertheless, other cases of sarcoidosis and morphea association should be reported to provide additional clinical and prognostic data.
